Carcinoma, Transitional Cell Clinical Trial
Official title:
A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract
This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01215877 -
Tesetaxel for Previously Treated Patients With Bladder Cancer
|
Phase 2 | |
| Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
| Terminated |
NCT02450331 -
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
|
Phase 3 | |
| Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT00077688 -
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
| Recruiting |
NCT05874921 -
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
|
||
| Completed |
NCT03410693 -
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 2/Phase 3 | |
| Completed |
NCT02451423 -
Neoadjuvant Atezolizumab in Localized Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00001381 -
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
|
Phase 1 | |
| Recruiting |
NCT05318339 -
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
| Completed |
NCT02443324 -
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
|
Phase 1 | |
| Completed |
NCT00722553 -
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
|
Phase 2 | |
| Recruiting |
NCT00146276 -
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
|
Phase 3 | |
| Completed |
NCT02014337 -
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT01189838 -
The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma
|
N/A | |
| Withdrawn |
NCT00172367 -
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
|
Phase 2 | |
| Completed |
NCT00191971 -
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
|
Phase 2 | |
| Terminated |
NCT04039867 -
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
|
Phase 2 | |
| Completed |
NCT01529411 -
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer
|
Phase 2 |